3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
5
Sarcoma, Ewing
3
Sarcoma
3
Endometrial Neoplasms
3
Neoplasms
2
Stomach Neoplasms
1
SCLC, Extensive Stage
1
Recurrence
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Mesothelioma
1
Glioblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Interventions
Dexamethasone
33
Cyclophosphamide
29
venetoclax
18
fludarabine
18
Lenalidomide
16
Bortezomib
16
Cytarabine
13
pembrolizumab
12
Calcium Dobesilate
12
Carboplatin
11
fludarabine phosphate
10
Rituximab
10
pomalidomide
9
Gemcitabine
9
Nivolumab
8
Azacitidine
7
daratumumab
6
carfilzomib
6
blinatumomab
6
Decitabine
6
Bendamustine Hydrochloride
6
selinexor
5
obinutuzumab
5
ibrutinib
5
Vincristine
5
Temozolomide
5
Methotrexate
5
Etoposide
5
Cisplatin
5
tafasitamab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recurrence
×
PM 01183
×
Clear all
NCT04358237
2025-06-04
LUPER
Blanco, Dr Antonio Calles MD
Phase 1/2
Completed
28 enrolled